EirGenix Inc. (6589) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of EirGenix Inc. TWD 6.50, price TWD 50.80, upside -87.2%, quality 48 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch EirGenix Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 40.55 TWD – 188.50 TWD · fair‑value band 4.29 TWD – 8.13 TWD · the 50.80 TWD price screens above the 6.50 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow EirGenix in your weekly email
Every Wednesday you see whether EirGenix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.
Show more
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage. In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein. The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.
Stock analysis
EirGenix Inc. (6589) currently trades at 50.80 TWD, while our model-based Fair Value estimate is 6.50 TWD, 87.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: 4.29 TWD (bear) to 8.13 TWD (bull), the price of 50.80 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
EirGenix Inc. reported revenue of 1.0B TWD in FY2025 versus 1.7B TWD in FY2021, a compound −12.3%/yr. Reported net income was −761M TWD in FY2025.
Key figures
Market cap 15.4B TWD (≈ $484M) · P/S ratio 12.2 · EPS (TTM) −1.87 TWD · Net margin −75.7% · Return on equity −7.0% · Return on assets (EBIT) −5.6% · Operating margin −64.7% · Revenue (TTM) 1.2B TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (low confidence).
What moves the price
The share trades about 38% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, 6589 screens richer than that median.
Fair Value models
Bear 4.29 TWDFair Value 6.50 TWDBull 8.13 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.1%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3.4% (2021) → −83.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Above median
Fair Value upside−87.2% · Bottom 25%
Profitability
Return on assets−5.1% · Above median
Net margin (TTM)−46.9% · Bottom 25%
Operating margin (TTM)−64.7% · Bottom 25%
Growth and dividend
Revenue growth35.4% · Top 25%
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B0.06× · Cheapest 25%
P/S (TTM)0.40× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)95· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "EirGenix Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6589
Frequently asked questions
Is EirGenix Inc. (6589) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 6.50 TWD versus a price of 50.80 TWD, about −87% upside (overvalued).
What is the fair value of 6589?
Our model-based fair value for EirGenix Inc. is 6.50 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 50.80 TWD.
What is the quality score of 6589?
EirGenix Inc. has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for EirGenix Inc. (6589)?
Our model-based price target is the fair value of 6.50 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 4.29 TWD, optimistic scenario 8.13 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the EirGenix Inc. stock forecast for 2026?
Our models put fair value at 6.50 TWD, about −87% upside versus a price of 50.80 TWD (overvalued). Cautious scenario 4.29 TWD, optimistic scenario 8.13 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of EirGenix Inc. (6589)?
EirGenix Inc. reported trailing-twelve-month revenue of about 1.2B TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of EirGenix Inc. (6589)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For EirGenix Inc. it is 6.50 TWD per share (as of Sep 24, 2026), against a price of 50.80 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is EirGenix Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6589 trades above its calculated fair value: price 50.80 TWD, fair value 6.50 TWD, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6589?
No. The price is what the market pays today (50.80 TWD); the fair value is what the company's own numbers justify (6.50 TWD). For EirGenix Inc. the two are 44.30 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is EirGenix Inc. worth?
The market values EirGenix Inc. at about 15.4B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 50.80 TWD; our models calculate a fair value of 6.50 TWD per share.
What do the bullish and bearish scenarios say about 6589?
Our models span a range for EirGenix Inc.: cautious scenario 4.29 TWD, base 6.50 TWD, optimistic 8.13 TWD per share (as of Sep 24, 2026, price 50.80 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of EirGenix Inc. (6589)?
Balance-sheet figures for EirGenix Inc. (as of Sep 24, 2026): return on equity −7.0%, debt of 0.11 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is 6589 from its 52-week high?
EirGenix Inc. trades at 50.80 TWD, about 38% below its 52-week high of 81.90 TWD and 25% above the low of 40.55 TWD (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 6.50 TWD is for.
Which stocks are comparable to EirGenix Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is EirGenix Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price 50.80 TWD, calculated fair value 6.50 TWD (−87%), Quality Score 48/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6589 calculated?
We run EirGenix Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 6.50 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. EirGenix Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of EirGenix Inc. (6589)?
The closing price on Oct 2, 2026 was 50.80 TWD. Our model-based fair value is 6.50 TWD, about −87% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with EirGenix Inc. right now?
The price sits above even our optimistic bull case (8.13 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (48/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (4.29 TWD to 8.13 TWD) leaves room in how you read the outcome.
Key figures of EirGenix Inc.
How large is the market capitalisation of EirGenix Inc. (6589)?
The market capitalisation of EirGenix Inc. is 15.4B TWD (≈ $484M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of EirGenix Inc. (6589)?
The price-to-sales ratio of EirGenix Inc. is 12.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of EirGenix Inc. (6589)?
Earnings per share at EirGenix Inc. are −1.87 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of EirGenix Inc. (6589)?
The net margin of EirGenix Inc. is −75.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of EirGenix Inc. (6589)?
The return on equity (ROE) of EirGenix Inc. is −7.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of EirGenix Inc. (6589)?
On an EBIT basis the return on assets of EirGenix Inc. is −5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of EirGenix Inc. (6589)?
The operating margin of EirGenix Inc. is −64.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at EirGenix Inc. (6589)?
Revenue at EirGenix Inc. is growing +35.4% versus a year earlier (3y avg −12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does EirGenix Inc. (6589) generate?
The free cash flow of EirGenix Inc. is −1.3B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed
Watch EirGenix Inc. in the live analysis
One click puts EirGenix Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
